U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H20FN3O4
Molecular Weight 361.3682
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOFLOXACIN ANHYDROUS

SMILES

C[C@@]1([H])COc2c3c(cc(c2N4CCN(C)CC4)F)c(=O)c(cn13)C(=O)O

InChI

InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H20FN3O4
Molecular Weight 361.3682
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Curator's Comment:: levofloxacin penetrates the cerebrospinal fluid (CSF) during meningeal inflammation both in animals and in humans

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

851040000000
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

851040000000
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

851040000000
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

851040000000
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

851040000000
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

851040000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.9 mg/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.8 mg/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.8 mg/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.85 mg/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.04 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.3 mg/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
49.6 mg × h/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
59 mg × h/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
118 mg × h/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
111 mg × h/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
19.88 mg × h/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55.3 mg × h/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.6 h
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.4 h
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.9 h
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.9 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.97 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.6 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources:
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources:
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.2%)
Nausea (0.6%)
Vomiting (0.5%)
Dizziness (0.3%)
Headache (0.3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 0.2%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Dizziness 0.3%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Vomiting 0.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Nausea 0.6%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Gastrointestinal disorder 1.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Headache 0.2%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Dizziness 0.3%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Vomiting 0.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Nausea 0.6%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Gastrointestinal disorder 1.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Dizziness 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Headache 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Vomiting 0.5%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Nausea 0.6%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
Gastrointestinal disorder 1.2%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources:
unhealthy, mean 50 years
Health Status: unhealthy
Age Group: mean 50 years
Sex: M+F
Sources:
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 136 uM]
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
2001
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
2001
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.
2001
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
2001 Apr
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
2001 Apr
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion.
2001 Apr
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
2001 Apr
[Use of levofloxacine in primary care for outbreaks in COPD].
2001 Apr 15
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.
2001 Aug 15
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.
2001 Feb
Quinolones alter defense reactions mediated by macrophages.
2001 Feb
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.
2001 Jan
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance].
2001 Jan-Feb
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
2001 Jul
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.
2001 Jul
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department.
2001 Jul
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
2001 Jul
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
2001 Jul
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.
2001 Jul
Levofloxacin and warfarin interaction.
2001 Jul
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
2001 Jul
Activity of levofloxacin and ciprofloxacin against urinary pathogens.
2001 Jul
Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa?
2001 Jul-Aug
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.
2001 Jun
Complicated urinary tract infections in patients with voiding dysfunction.
2001 Jun
Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy.
2001 Jun
Levofloxacin failure in a patient with pneumococcal pneumonia.
2001 Jun
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece.
2001 Jun
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
2001 Jun
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
2001 Jun
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
2001 Jun
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.
2001 Mar
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
2001 Mar
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice.
2001 Mar
Treatment of tularemia with levofloxacin.
2001 Mar
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
2001 Mar
A case of renal involvement in persistent immune activation caused by chlamydial salpingitis.
2001 Mar
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.
2001 May
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
2001 May
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
2001 May
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery.
2001 May
Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
2001 May
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.
2001 May
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.
2001 May
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.
2001 May 15
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
2001 May-Jun
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
2001 May-Jun
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
2001 May-Jun
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.
2001 May-Jun
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
2001 Spring
Patents

Sample Use Guides

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours.
Route of Administration: Other
In Vitro Use Guide
Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:55:15 UTC 2021
Edited
by admin
on Fri Jun 25 21:55:15 UTC 2021
Record UNII
RIX4E89Y14
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOFLOXACIN ANHYDROUS
Common Name English
OFLOXACIN S-(-)-FORM [MI]
Common Name English
OFLOXACIN S-(-)-FORM
MI  
Common Name English
LEVOFLOXACIN [WHO-DD]
Common Name English
NSC-758709
Code English
LEVOFLOXACIN [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC J01MA12
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
WHO-ATC S01AX19
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
Code System Code Type Description
HSDB
8028
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
EVMPD
SUB08471MIG
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
FDA UNII
RIX4E89Y14
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
DRUG BANK
DB01137
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
NCI_THESAURUS
C170539
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
CAS
100986-85-4
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
RXCUI
1546009
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY RxNorm
INN
6708
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
PUBCHEM
149096
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
EVMPD
SUB127353
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
MERCK INDEX
M8133
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY Merck Index
EPA CompTox
100986-85-4
Created by admin on Fri Jun 25 21:55:15 UTC 2021 , Edited by admin on Fri Jun 25 21:55:15 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
IC50
SALT/SOLVATE -> PARENT
SUBSTANCE->BASIS OF STRENGTH
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites
URINE
METABOLITE LESS ACTIVE -> PARENT
Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites
URINE
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY